Market Flux Event
Eli Lilly Wins First-Ever China Approval for an Oral GLP-1 Weight-Loss Drug, Topping Novo Nordisk
Read this in the Market Flux appEli Lilly became the first drugmaker to receive Chinese regulatory approval for a GLP-1 weight-loss pill on November 12, giving the Indianapolis-based company a significant first-mover advantage over Danish rival Novo Nordisk in the world's second-largest pharmaceutical market. The approved drug is orforglipron, an oral pill that now enters the Chinese market ahead of any competing oral GLP-1 therapy.
Orforglipron will compete in China against Lilly's own once-weekly GLP-1 weight-loss injection as well as rival injections from Novo Nordisk, Pfizer, and Chinese company Innovent Biologics. The approval of a pill, which many patients prefer over weekly injections, hands Lilly a distinct format advantage in a market of enormous commercial potential. Lilly shares rose as much as 3% in premarket trading on the news.
© AI-generated summary is provided by Market Flux
Sources
- ReutersEli Lilly becomes first drugmaker to have a GLP-1 weight loss pill approved in China
- FirstSquawkELI LILLY SHARES UP 2% PREMARKET AFTER CO BECOMES THE FIRST DRUGMAKER TO HAVE GLP-1 WEIGHT LOSS PILL APPROVED IN CHINA.
- Seeking AlphaChina approves Eli Lilly's GLP-1 weight-loss pill, giving it lead over Novo - report
- BioStocks$PHVS Topline data from part 1 of CREAATE pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks expected in Q1
- TheTradeXchange$MRNA - Moderna Outlines Next Phase of Growth at Analyst DayHighlights intismeran and cancer antigen therapies as foundational opportunities for a growing oncology franchiseDetails commercial and manufacturing readiness for intismeran following positive Phase 3 results in adjuvant melanomaHighlights multiple levers to improve infectious disease vaccine franchise profitabilityOutlines mid-term financial strategy focused on growth and disciplined capital allocation
- Newsfile_CorpPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Full Story: #PhioPharma11803 $PHIO #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #HealthCare
- MarketsdayLupin launches biosimilar Ranibizumab through Sandoz in Europe except Germany Ranluspec approved by European Commission in vial and pre-filled syringe forms for retinal disease treatment
- InvestingAltimmune publishes 48-week pemvidutide trial results in Lancet
Show 5 more
- Business WireTakeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
- OpenOutcrier$ENGN (+7.2% pre) enGene reports improved efficacy data for bladder cancer therapy
- NasdaqAstellas, Immuneering Enter Pancreatic Cancer Trial Collaboration
- BPharmCatalyst$ADXN announced former subsidiary Neurosterix raised $105 million in Series B funding post-Phase 1 trials to advance oral M4 receptor modulator NTX-253 into Phase 2 for schizophrenia. Addex skipped participation, diluting its stake to 8.5% (worth $18.6 million), while ADXN shares jumped 110% overnight to $6.00 on the residual valuation. $ENGN $OPRX $XAIR $ICU $ADXN $ALVO $ALGS $PCSA $XBIO $CODX See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
- Proactive_X$BIAF bioAffinity posts record month for CyPath Lung cancer test @bioAffinity #BIAF